Autonomic problems in Charcot–Marie–Tooth disease
AUTONOMOUS DISORDERS IN CMT
This study will test how common and how severe autonomic (automatic nervous system) symptoms are in adults aged 18–65 with genetically confirmed Charcot–Marie–Tooth disease compared with healthy volunteers.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 50 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | University Medical Center Goettingen Academic / other |
| Locations | 1 site (Göttingen, Lower Saxony) |
| Trial ID | NCT07570446 on ClinicalTrials.gov |
What this trial studies
Participants with genetically confirmed CMT and an anamnestically healthy control group will complete symptom questionnaires and undergo non-invasive autonomic function tests to document presence and severity of autonomic dysfunction. Investigators will collect clinical data including genotype, disease duration, neurological impairment severity, and comorbidities. The study is observational and conducted at a single academic center, aiming to describe prevalence and characterize autonomic features rather than test an intervention. Data will be used to better define how autonomic symptoms contribute to daily functioning and quality of life in CMT patients.
Who should consider this trial
Good fit: Adults aged 18–65 with a clinical and genetic diagnosis of CMT who can give informed consent and complete baseline outcome measures, as well as consenting healthy control volunteers, are eligible.
Not a fit: Individuals outside the 18–65 age range, those who are pregnant or breastfeeding, or those with other relevant neurological, psychiatric, or serious internal diseases are unlikely to benefit from participation.
Why it matters
Potential benefit: If successful, the findings could help clinicians recognize and manage autonomic symptoms in CMT patients, potentially improving daily functioning and quality of life.
How similar studies have performed: Previous smaller studies and case reports have reported autonomic symptoms in CMT, but comprehensive systematic data on prevalence and characteristics are limited.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Clinical CMT Diagnosis / Anamnestically Healthy Control Group * Genetic confirmation of CMT in adult patients * Ability to achieve the outcome measure at baseline * Age between 18 and 65 years * Capacity of all study participants to consent and signed informed consent, - including patient or participant information and consent form Exclusion Criteria: * Pregnancy or breastfeeding period * Other relevant neurological or psychiatric disorders, acute or in the past history * Presence of a serious previous internal disease
Where this trial is running
Göttingen, Lower Saxony
- University Medical Centre — Göttingen, Lower Saxony, Germany (Recruiting)
Study contacts
- Study coordinator: Michael W Sereda, Prof. MD
- Email: sereda@mpinat.mpg.de
- Phone: +49 551 3964162
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.